How many drugs treat Status epilepticus?

Drug Landscape tracks 10 marketed treatments for Status epilepticus (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

What's the most recent regulatory action in Status epilepticus?

Most recent: Keppra — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/status-epilepticus.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Status epilepticus — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Status epilepticus (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Status epilepticus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Keppra	levetiracetam	Generic (originally UCB Pharma)	Antiepileptic agent	Synaptic vesicle protein SV2A	1999-11-30
Cerebyx	FOSPHENYTOIN	Pfizer	Anti-epileptic Agent	Sodium channel protein type 5 subunit alpha	1996-01-01
Versed	midazolam	Generic (originally Roche)	Benzodiazepine (short-acting)	Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2	1985-12-20
Versed	Midazolam Hydrochloride	Takeda Pharmaceutical Company Limited	Benzodiazepine	GABA A receptor alpha-5/beta-2/gamma-2	1985-01-01
Ativan	lorazepam	Generic (originally Wyeth/Pfizer)	Benzodiazepine [EPC]	GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver	1977-09-30
Nembutal Sodium	PENTOBARBITAL	Oak Pharms	pentobarbital	GABA-A receptor alpha-1/beta-2/gamma-2	1973-01-01
Valium	diazepam	Generic (originally Roche)	Benzodiazepine [EPC]	Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2	1963-11-15
Phenytoin Sodium	PHENYTOIN	Viatris	Anti-epileptic Agent	Sodium channel protein type 2 subunit alpha	1953-01-01
Dilantin	Phenytoin Sodium	Pfizer	phenytoin	Nuclear receptor subfamily 1 group I member 3	1953-01-01
Keppra	Keppra	Masonic Cancer Center, University of Minnesota		Carbonic anhydrase 1, Sodium channel protein type 1 subunit alpha, Synaptic vesicle glycoprotein 2A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-05-08 — Keppra · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Generic (originally Roche) · 2 drugs in Status epilepticus
Pfizer · 2 drugs in Status epilepticus
Generic (originally Wyeth/Pfizer) · 1 drug in Status epilepticus
Masonic Cancer Center, University of Minnesota · 1 drug in Status epilepticus
Oak Pharms · 1 drug in Status epilepticus
Takeda Pharmaceutical Company Limited · 1 drug in Status epilepticus
· 1 drug in Status epilepticus
Viatris · 1 drug in Status epilepticus
Generic (originally UCB Pharma) · 1 drug in Status epilepticus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Status epilepticus:

Cite this brief

Drug Landscape (2026). Status epilepticus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/status-epilepticus. Accessed 2026-06-10.

Status epilepticus full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing